NautaDutilh advised Merus N.V., a clinical-stage oncology company, in raising approximately USD 460 million in gross proceeds through an upsized underwritten public offering of 8,682,500 common shares.
This offering included the underwriter's option to purchase an additional 1,132,500 common shares at a public offer price of USD 53.00 per share. All the shares in the offering were sold by Merus.
“We are pleased to have assisted our longstanding client Merus in this significant transaction as they continue their journey to clinically advance targeted treatments to address unmet needs of patients with various types of cancer.”
NautaDutilh's team advising on the transaction was led by Paul van der Bijl, supported by Sanne Mesu, Joppe Schoute, Mohamad Jabari, Nina Kielman and Nick Roovers. The team worked alongside the US team of Latham & Watkins.